Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.57 -4.6%	$1.48	$1.01 ▼ $3.31	$443.94M	1.07	1.39 million shs	380,863 shs
KMDA Kamada	$7.25 -1.4%	$7.46	$5.17 ▼ $9.15	$417.77M	0.93	133,460 shs	47,191 shs
KOD Kodiak Sciences	$10.64 +0.6%	$5.58	$1.92 ▼ $11.60	$559.84M	2.41	436,251 shs	597,532 shs
SAVA Cassava Sciences	$2.29 -2.4%	$2.15	$1.15 ▼ $33.98	$110.82M	-2.05	1.44 million shs	703,263 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	0.00%	+17.14%	+9.33%	+33.33%	-41.43%
KMDA Kamada	0.00%	+3.23%	-1.34%	+7.77%	+32.67%
KOD Kodiak Sciences	0.00%	+33.80%	+91.49%	+184.91%	+327.94%
SAVA Cassava Sciences	0.00%	+7.34%	+5.88%	+13.04%	-91.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.4362 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
KMDA Kamada	4.6338 of 5 stars	3.3	5.0	0.0	3.2	1.7	4.4
KOD Kodiak Sciences	2.4327 of 5 stars	1.0	1.0	4.6	2.5	3.3	0.0
SAVA Cassava Sciences	2.1026 of 5 stars	1.0	1.0	4.7	2.1	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	2.86	Moderate Buy	$4.29	173.85% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	79.41% Upside
KOD Kodiak Sciences	2.00	Hold	$11.75	10.48% Upside
SAVA Cassava Sciences	2.00	Hold	$2.00	-12.47% Downside

Current Analyst Ratings Breakdown

Latest SAVA, KOD, KMDA, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00 ➝ $2.00
8/18/2025	KOD Kodiak Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $5.00
8/14/2025	KOD Kodiak Sciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$4.00 ➝ $7.00
8/14/2025	KOD Kodiak Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$15.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.50 per share	N/A
KMDA Kamada	$169.52M	2.46	$0.48 per share	14.95	$4.51 per share	1.61
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	N/A
KMDA Kamada	$14.46M	$0.34	21.37	22.64	0.78	11.22%	7.41%	5.18%	N/A
KOD Kodiak Sciences	-$176.21M	-$3.80	N/A	N/A	N/A	N/A	-155.27%	-63.29%	N/A
SAVA Cassava Sciences	-$24.34M	-$2.55	N/A	N/A	N/A	N/A	-59.54%	-50.16%	N/A

Latest SAVA, KOD, KMDA, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SAVA Cassava Sciences	N/A	-$0.18	N/A	-$0.92	N/A	N/A
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/13/2025	Q2 2025	KOD Kodiak Sciences	-$1.01	-$1.03	-$0.02	-$1.03	N/A	N/A
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.03	11.04
KMDA Kamada	N/A	4.00	2.21
KOD Kodiak Sciences	N/A	3.48	3.48
SAVA Cassava Sciences	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
KMDA Kamada	20.38%
KOD Kodiak Sciences	89.06%
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
KMDA Kamada	36.10%
KOD Kodiak Sciences	45.90%
SAVA Cassava Sciences	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.67 million	242.82 million	Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
KOD Kodiak Sciences	90	52.82 million	28.58 million	Optionable
SAVA Cassava Sciences	30	48.31 million	42.41 million	Optionable

SAVA, KOD, KMDA, and ERAS Headlines

Recent News About These Companies

Cassava Sciences, Inc.: Cassava Reports Q2 2025 Financials Results and Provides Business Update

August 14, 2025 | finanznachrichten.de

Cassava Sciences reports Q2 EPS (92c) vs 13c last year

August 14, 2025 | msn.com

Cassava Reports Q2 2025 Financials Results and Provides Business Update

August 14, 2025 | globenewswire.com

Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer

August 7, 2025 | globenewswire.com

Ginkgo Bioworks Holdings Q2 Earnings Preview

August 6, 2025 | msn.com

Cassava Sciences Announces Positive Preclinical Results

August 6, 2025 | theglobeandmail.com

Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy

August 4, 2025 | globenewswire.com

Gallacher Capital Management LLC Decreases Stock Holdings in Cassava Sciences, Inc. (NASDAQ:SAVA)

July 23, 2025 | marketbeat.com

SAVA - Cassava Sciences Inc Sustainability - Morningstar

July 2, 2025 | morningstar.comM

Cassava Sciences presents poster at TSC 2025 on Simufilam

June 30, 2025 | msn.com

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

June 30, 2025 | globenewswire.com

SAVA Stock Price for Cassava Sciences Inc - Morningstar

June 28, 2025 | morningstar.comM

Why cassava could be a great addition to a balanced diet

June 26, 2025 | msn.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava partners with Zindi to give African AI developers better tools

May 15, 2025 | techzim.co.zwT

Cassava Sciences Inc.

May 15, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.comK

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.comT

Cassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU Ecosystem

May 12, 2025 | devdiscourse.comD

New MarketBeat Followers Over Time

Media Sentiment Over Time

SAVA, KOD, KMDA, and ERAS Company Descriptions

Erasca NASDAQ:ERAS

$1.56 -0.08 (-4.57%)

As of 02:43 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Kamada NASDAQ:KMDA

$7.25 -0.10 (-1.41%)

As of 02:43 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Kodiak Sciences NASDAQ:KOD

$10.64 +0.07 (+0.61%)

As of 02:44 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Cassava Sciences NASDAQ:SAVA

$2.28 -0.06 (-2.35%)

As of 02:43 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time